Ming-Yuan Chen, MD,PhD
Sun Yat-sen University
8
8
1
N/A
0
6
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+11 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Ming-yuan Chen, MD, PhD
Sun Yat-sen University
Shared therapeutic areas:
Worked with same sponsors:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Jun Ma, M.D.
Sun Yat-sen University
Shared therapeutic areas:
Worked with same sponsors:
Sirilak Suksompong, MD
Mahidol University
Shared therapeutic areas:
Herui Yao, PhD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shared therapeutic areas:
Worked with same sponsors:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Michael S Avidan, MBBcH
Washington University School of Medicine
Shared therapeutic areas:
Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.
Shared therapeutic areas:
Dong-Xin Wang, MD,PhD
Peking University First Hospital
Shared therapeutic areas:
Nieto Luis, Master
Site Coordinator of United Medical Group located in Miami
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
All 8 trials loaded